Kash In Kalkine Media

The healthcare sector across the world has come to the rescue of the human race, as the second line of attack against the coronavirus pandemic. The first one, of course, being the health authorities who have put in all efforts to contain the spread of the virus and treating the already infected and saving as many lives as they can. Why is it said that the British Vaccine Developers have an advantage over other competitors in the world? Lets also look at some noteworthy biopharma companies.

Westpac Banking Corporation (ASX: WBC) is engaged in the banking and financial services related activities.The bank recently gave notice of the aggregated percentage of voting shares in the company, in respect of which its controlled entities have the power to control voting or disposal of in accordance with the terms of an exemption granted by the Australian Securities and Investments Commission pursuant to subsection 259C (2) of the Corporations Act 2001.

New pre-clinical data from ongoing studies supports further clinical evaluation of BNC101:Bionomics Ltd has recently released new pre-clinical data from ongoing studies of BNC101, cancer drug candidate being developed to treat solid cancer. The data presented at the annual American Association for Cancer Research conference in Washington, DC demonstrates complementary anti-tumor activity between BNC101 and checkpoint inhibitors (Checkpoint inhibitors seek to overcome one of cancer's main defenses against an immune system attack). The data strongly supports further clinical evaluation of BNC101 in combination with checkpoint inhibitors. Although a concrete outlook/ guidance on financials has not been provided for full year, BNO expects to continue with its investments in pipeline programs.

Fiscal Year 2016 performance was as forecasted: Seven West Media Ltd (SWM) lately signed a contract to acquire Sunday Times and PerthNow and expect these to increase the shareholder value and deal with the challenges of fragmented market in Western Australia. The group delivered as per the full year guidance in Fiscal Year 2016 and reported a 0.9% fall in underlying net profit after tax (excluding significant items) to $207.3 million. The group reported about 3% fall in the revenues to $1,726.6 million against fiscal year of 2015. Moreover, the group is accelerating the transformation of its business across all platforms. The group’s digital segment is expected to deliver greater than 150% of revenue growth.

Automotive Holdings Group LtdBoosted Capital position from acquisitions: Automotive Holdings Group Ltd (ASX: AHG) stated that it’s Share Purchase Plan has closed oversubscribed following successful completion of fully underwritten placement to raise $90 million. Automotive Holdings earlier reported a 7.2% increase in revenues to $5.25 billion in Fiscal Year 2016 and the earnings per share grew 2.4% to 28.7 cents per share, which is slower than operating profit primarily due to costs related to acquisitions and a few one-offs including impairment of assets. The statutory Net Profit After Tax grew 2.2% to $90.1 million. The stock rose over 17.62% in the last three months and still trading at a decent dividend yield.

Strong market presence: LifeHealthcare Group Ltd (ASX: LHC) enjoys top three market positions in core channels. The business model is focused on global sourcing and offering local solutions with emphasis on specialty clinical channels and products like spine, neurosurgery, orthopedics, ultrasound and coronary intervention. Meanwhile, the group’s revenues have grown at a CAGR of 10.3% since the last five years while EBITDA grew 14.3% during the same period. Moreover, the demand outlook remains positive with rising aging population, emerging technology and rising rate of chronic disease.